A retrospective study on the use of immunoglobulin therapy in pediatric patients: Indications, dosage, and side effects in the Qassim Region, Saudi Arabia.
Saved in:
| Title: | A retrospective study on the use of immunoglobulin therapy in pediatric patients: Indications, dosage, and side effects in the Qassim Region, Saudi Arabia. |
|---|---|
| Authors: | Alkhuwaiter, Raghad Abdullah (AUTHOR), Alghasham, Yazeed A. (AUTHOR), Alharbi, Mariyyah Muqbil (AUTHOR), Almoutiri, Ashwaq Mohammed (AUTHOR), Alharbi, Tuqa Yousif (AUTHOR), Alaqeel, Shahad Abdalaziz (AUTHOR), Alosaily, Yousif (AUTHOR), Alrasheed, Ali Mohammed (AUTHOR) |
| Source: | Saudi Journal for Health Sciences. Jan-Apr2026, Vol. 15 Issue 1, p41-45. 5p. |
| Subjects: | Intravenous immunoglobulins, Child patients, Drug side effects, Serotherapy, Retrospective studies, Saudi Arabians |
| Geographic Terms: | Saudi Arabia |
| Abstract: | Background: Intravenous immunoglobulin (IVIG) is a plasma product which has been extracted from the serum of thousands of donors. It has been approved by the federal drug authority (FDA) either as an immune-replacement or immune-modulation therapy. The use of IVIG has recently been extended to multiple diseases, some of which are still not approved by the FDA showing a good clinical response. There are limited data published from Saudi Arabia reporting the use of IVIG therapy encompassing clinical indicators, dosing protocols, and related adverse events. Aim: The Aim if this study was to evaluate the prevalence and frequency of IVIG therapy among pediatric patients and to evaluate the indications and subspecialties prescribed the IVIG therapy. Methods: This retrospective study included the patients who received treatment between March 2023 and March 2025. The data extracted from medical records included demographics as well as variables related to IVIG therapy. Results: There were 229 patients who received IVIG therapy during the study period. There were 38.4% of patients <2 years old, and 22.7% of patients were between 2.1 and 5 years old. The highest prescription of IVIG was by neonatology. The most common indication was idiopathic thrombocytopenic purpura (25.85%). Dose accuracy was significantly affected by the category of IVIG, in which accuracy was compromised significantly for Category C IVIG therapy compared to Category A and Category B (P < 0.001). Conclusion: In our study we observe that there are multiple departments are using IVIG for off-label indications that is NOT approved officially by the FDA which could be risky for the patients and also having financial burden on the hospital. It was required to take corrective measures to improve this practice. [ABSTRACT FROM AUTHOR] |
| Copyright of Saudi Journal for Health Sciences is the property of Wolters Kluwer India Pvt Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Intravenous immunoglobulin (IVIG) is a plasma product which has been extracted from the serum of thousands of donors. It has been approved by the federal drug authority (FDA) either as an immune-replacement or immune-modulation therapy. The use of IVIG has recently been extended to multiple diseases, some of which are still not approved by the FDA showing a good clinical response. There are limited data published from Saudi Arabia reporting the use of IVIG therapy encompassing clinical indicators, dosing protocols, and related adverse events. Aim: The Aim if this study was to evaluate the prevalence and frequency of IVIG therapy among pediatric patients and to evaluate the indications and subspecialties prescribed the IVIG therapy. Methods: This retrospective study included the patients who received treatment between March 2023 and March 2025. The data extracted from medical records included demographics as well as variables related to IVIG therapy. Results: There were 229 patients who received IVIG therapy during the study period. There were 38.4% of patients <2 years old, and 22.7% of patients were between 2.1 and 5 years old. The highest prescription of IVIG was by neonatology. The most common indication was idiopathic thrombocytopenic purpura (25.85%). Dose accuracy was significantly affected by the category of IVIG, in which accuracy was compromised significantly for Category C IVIG therapy compared to Category A and Category B (P < 0.001). Conclusion: In our study we observe that there are multiple departments are using IVIG for off-label indications that is NOT approved officially by the FDA which could be risky for the patients and also having financial burden on the hospital. It was required to take corrective measures to improve this practice. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 22781900 |
| DOI: | 10.4103/sjhs.sjhs_165_25 |
